Spiraling Costs: Who Will Address the Role of Medicolegal Drivers?

Article

I think it is a real shame that inside the Beltway, both sides of the political arena have had neither the wisdom nor the courage to recognize and address the fact that medicolegal drivers will continue to push costs upward until someone takes the lead in tackling this issue.

Derek Raghavan, MD

Carolinas HealthCare System (CHS) has always taken care of indigent patients and has thus practiced the philosophy embedded in Michael Porter's more recent treatise on redefining health care. Thus CHS and its Levine Cancer Institute will continue to provide care to all patients with cancer and allied disorders. We recognize that costs need to be reduced and efficiencies and quality increased, and these objectives are embedded in our work.

I think it is a real shame that inside the Beltway, both sides of the political arena have had neither the wisdom nor the courage to recognize and address the fact that medicolegal drivers will continue to push costs upward until someone takes the lead in tackling this issue.

More on the Supreme Court Decision

Derek Raghavan
Bruce Minsky
Nora Janjan
Michael Glod
James B. Yu
Lawrence Wagman
Recent Videos
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
“This is something where this is written by the trainees, for the trainees, and, of course, for all the other clinicians who take care of patients,” said Kiran Turaga, MD, MPH.
“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
The new peritoneal surface malignancy care guidelines had clinicians gather from every disease state to show increased representation.
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
A combined cohort composed of patients from the TROPION-Lung01 and TROPION-Lung-05 trials showed a survival advantage with dato-DXd vs docetaxel.
Related Content
The independent data monitoring committee confirmed the favorable safety profile of ELI-002 7P for the treatment of PDAC in the phase 1/2 AMPLIFY-7P trial.

IDMC Recommends Continuation of ELI-002 7P Trial in PDAC

Roman Fabbricatore
August 5th 2025
Article

The independent data monitoring committee confirmed the favorable safety profile of ELI-002 7P for the treatment of PDAC in the phase 1/2 AMPLIFY-7P trial.

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management

Jacob Sands, MD
August 4th 2025
Podcast

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

At 4 years, about 20% of patients with advanced melanoma who received tumor-infiltrating lymphocyte therapy were alive and responding to treatment.

TIL Therapy Provides Excitement Despite Room to Grow in Melanoma Care

Tim Cortese
August 5th 2025
Article

At 4 years, about 20% of patients with advanced melanoma who received tumor-infiltrating lymphocyte therapy were alive and responding to treatment.

Navigating Second-Line Treatment Options in Urothelial Carcinoma

Navigating Second-Line Treatment Options in Urothelial Carcinoma

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
July 31st 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, focus on treatment options for patients with urothelial carcinoma.

More work is needed to expand access to novel CAR T-cell therapies and bispecific agents among community oncologists, according to Al-Ola A. Abdallah, MD.

Developing a Bridge to Optimize Cellular Therapy Use in Multiple Myeloma

Russ Conroy
August 4th 2025
Article

More work is needed to expand access to novel CAR T-cell therapies and bispecific agents among community oncologists, according to Al-Ola A. Abdallah, MD.

Explicating Early-Line Treatment Considerations for EGFR-Mutant NSCLC

Explicating Early-Line Treatment Considerations for EGFR-Mutant NSCLC

Roman Fabbricatore
August 4th 2025
Article

Following the approval of dato-DXd in untreated EGFR-mutant NSCLC, Jacob Sands, MD, discussed next steps for improving outcomes for this disease.